Technology Bundle ID
TAB-2023

Biological/Research Material for HIV Vaccine Research

Linked ID
E-258-2009-0
Lead Inventors
Bernard Moss (NIAID)
Co-Inventors
Linda Wyatt (NIAID)
Development Status
Fully developed. Material has been used extensively in research.
Disease Areas
ICs
Offered for licensing is a recombinant attenuated vaccinia virus, MVA, that expresses SIV 239gagpol. The materials can be used for research purposes and in particular in the area of HIV/AIDS vaccines.

Plasmid insertion vector pJH-4, containing the foreign gene SIV 239 GagPol controlled by vaccinia early/late promoter, inserts into del III of attenuated vaccinia MVA virus to make recombinant MVA virus. The resulting recombinant virus made from pJH4, MVA/SIV239gagpol, expresses the SIV 239gagpol gene and thus can be used to conduct vaccine studies in animal models such as Rhesus macaques.

The list of publications shown below demonstrates the usefulness of this biological material in HIV vaccine research.
Commercial Applications
  • Research reagents useful in research and development in the area of HIV/AIDS vaccines.
Competitive Advantages
CB Process - Initiated CB Process. Forwarded email to LPM. Requesting details concerning the new technology.

Request More Info

Licensing Contact: